Clinical Trial Update: Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) [Phase 4]

View source ↗

Summary

Phase 4 EMPOWER trial evaluating switching from cabotegravir plus rilpivirine to bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 infection; results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)
• cabotegravir + rilpivirine (cabotegravir; rilpivirine)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1-infection | Phase 4 | Status: COMPLETED | Results posted: 2026-02-11